Every Cure Uses AI Tool to Match Patients with Medications
David Fajgenbaum led a team that developed artificial intelligence powered technology that matches rare diseases with existing medications.
Berger Lab Makes Discovery Linking cellular structures to kidney cancer treatment outcomes
These findings could pave the way for personalized treatments, matching patients to drugs based on their tumor's speckle pattern.
iECURE Reports on Preliminary Clinical Response Data in First Infant Dosed with its in vivo Gene Editing Candidate ECUR-506
iECURE reported preliminary findings from the first infant dosed with its in vivo gene editing candidate ECUR-506.
ViTToria Biotherapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of its VIPER-101 T-Cell Therapy
ViTToria has dosed the first patient in its Phase 1 clinical trial for VIPER-101.
āshibio Moves Forward with Clinical Trial
āshibio announced the dosing of the first participant in its Phase 2/3 clinical trial for its lead candidate, andecaliximab.
Cogwear Featured as a Startup to Watch in 2025
Cogwear was listed as one of PHL Inno’s Startups to Watch.
Interius Ranks in Top Ten of Capital Raises by Philadelphia Startups in 2024
Interius was recognized in the Philadelphia Business Journal’s “PHL Inno 2024 in Review” as one of the top Philadelphia-area startups raising capital last year.
Penn Spinout Gemma Therapeutics Raises $34 million to Develop Gene Therapies for Rare Diseases
Gemma Bio raised $34 million in a seed round led by Double Point Ventures, Bioluminescence Ventures and Earlybird Venture Capital.
Franklin Biolabs Names its First CEO
Franklin Biolabs, a Penn spinout founded by James Wilson, MD, PhD, Rose H. Weiss Professor in Penn Medicine, has named Vatsala Naageshwaran as its first chief executive officer.
Ocuphire Pharma Announces Acquisition of Opus Genetics, a Penn startup based on technology developed by Dr. Jean Bennett and colleagues
The merger between Opus and Ocuphire creates a transformative biotech company, renamed Opus Genetics, Inc, which is committed to the development of gene therapies for the treatment of IRDs.